OmniComm Systems Appoints Thomas Wells as Vice President of Technical Operations
Experienced industry veteran joins OmniComm’s executive team to drive technology operations for leading electronic data capture (EDC) company.
FT. Lauderdale, FL-June 2, 2008-OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that Thomas Wells has joined OmniComm to spearhead technology operations for the rapidly growing eClinical solutions company. Wells brings a strong pharmaceutical and health care background to the position. He will be responsible for driving strategy and delivering business processes and systems for product development as OmniComm delivers integrated solutions to meet industry demand.
Prior to joining OmniComm, Wells served as director, research and development informatics at Amgen, Inc. In his role at Amgen, he managed global teams that implemented and supported all of Amgen’s development systems. The teams implemented over 50 new clinical trials annually and maintained approximately 100+ trials in both EDC and Oracle Clinical. In addition, part of his responsibilities included expanding the global EDC program into large Phase II and III clinical trials. Prior to Wells’ tenure at Amgen, he worked for Integrium, a clinical research organization, as director, information technology where he developed and implemented all clinical trials management systems and all data management systems to fully integrate and interface with OCR, EDC, and other external sources. He also partnered with QA and was responsible for all sponsor audits.
Before joining Integrium, Wells served as senior systems architect for Ultralink Inc., a Web-based health care system and EDI solutions company. Prior to that, he held positions with Cocensys, Inc, a CNS biopharmaceutical company, Specialized Clinical Services, Inc., Long Beach Genetics, Inc., and Eastman Kodak, Clinical Products Division.
“Thomas’s exceptional industry credentials are a welcome addition to the OmniComm team and we look forward to benefiting from his strategic vision for technical operations," said Cornelis F. Wit, chief executive officer for OmniComm. “He brings a plethora of industry knowledge and experience that will help OmniComm bring to fruition the next generation eClinical products and solutions that our clients demand.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
